11.35
-0.28(-2.41%)
Currency In USD
Address
1055 West Hastings Street
New York City, BC V6E 2E9
Canada
Phone
650 208 2454
Website
Sector
Healthcare
Industry
Biotechnology
Employees
74
First IPO Date
November 15, 2016
| Name | Title | Pay | Year Born |
| Mr. Robert Barrow | Chief Executive Officer & Director | 997,010 | 1989 |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 306,402 | 1957 |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary | 638,607 | 1971 |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 703,319 | 1980 |
| Mr. Leonard Latchman | Co-Founder | 0 | N/A |
| Mr. Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | 0 | N/A |
| Dr. Gregg Pratt Ph.D. | Chief Regulatory & Quality Assurance Officer | 0 | N/A |
| Ms. Stephanie Fagan | Chief Corporate Affairs Officer | 0 | N/A |
| Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer | 0 | 1974 |
| Ms. Beth Calitri | Vice President of Corporate Communications | 0 | N/A |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.